Biocept Continues International Expansion through Agreement with Quest Diagnostics Mexico

"Our high sensitivity test uses a simple blood sample to provide a cost-effective, viable option for patients with lung cancer who are often too sick for invasive tissue sampling," said Raaj Trivedi, Vice President of Commercial Operations at Biocept.  "Detecting the EGFR mutation can qualify patients for targeted therapy treatments that could lead to better outcomes." 

"We are pleased to collaborate with Quest Diagnostics Mexico to make our test more accessible to the many patients in Mexico with lung cancer," added Mr. Trivedi.  "This collaboration also furthers our objective of actively expanding into geographies outside the U.S. and follows our recently announced distribution agreement for Israel."

"As an industry leader in the liquid biopsy space, we are providing comprehensive biomarker analysis in a rapid and cost-effective manner," said Michael Nall, President and CEO of Biocept. "Our ability to expand internationally is a testament to the scalability of our platform as we deliver liquid biopsy testing to the medical community worldwide."

About Biocept  
Biocept, Inc. is a molecular diagnostics company with commercial tests targeting lung, breast, gastric, colorectal and prostate cancers and melanoma.  The company uses its proprietary liquid biopsy technology to provide physicians with more precise information for treating and monitoring patients with cancer.  The company's patented Target Selector™ liquid biopsy technology platform captures and analyzes circulating tumor DNA in both circulating tumor cells (CTCs) and in plasma (ctDNA).  After thousands of tests, the platform has proven to be effective in identifying cancer mutations.  Biocept plans to introduce additional CLIA-validated tests in the near term.  For additional information, please visit www.biocept.com.

Forward-Looking Statements  
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve outcomes for cancer patients and enhance individual treatments of cancer, our ability to expand into geographies outside the U.S., our ability to scale our platform and our plans to introduce CLIA-validated tests in the near term , such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.